Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04475081 · ClinicalTrials.gov registry record · Phase 3
Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis
A Phase 3 study, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT04475081 is a Phase 3 study that has completed, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 50 participants.
The verdict
NCT04475081, a Phase 3 study, has completed, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes that can prevent/dampen pathological inflammation and sepsis associated with COVID-19-infection, if exposed.
Interventions
- BIOLOGICAL MMR vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2022-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04475081
The ClinicalTrials.gov registry entry for NCT04475081 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Louisiana State University Health Sciences Center in New Orleans, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MMR vaccine is the first listed.
NCT04475081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04475081 about?
NCT04475081 is a clinical study titled "Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis". The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes...
What is the current status of trial NCT04475081?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2020-09-22. Estimated completion is 2022-05-15.
What interventions are being tested in trial NCT04475081?
The interventions under investigation include: MMR vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04475081?
This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.